National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved May 1998

Specific Treatments:

acute organ transplant rejection

General Information

Simulect has been approved for acute rejection episodes in renal transplant recipients.

Mechanism of Action

Simulect works by blocking the receptor for IL-2, a protein that simulates proliferation of T-lymphocytes, which play a key role in organ transplant rejection.